A groundbreaking study has revealed that GLP-1 receptor agonists, including the popular weight-loss drug Ozempic, could significantly lower the risk of alcohol and opioid overdoses. This discovery suggests potential new applications for these drugs beyond their current use for obesity and diabetes.